Suppr超能文献

3-(氨甲基)萘醌曼尼希碱新型铂(II)配合物的合成、晶体结构与细胞毒性研究。

Novel platinum(II) complexes of 3-(aminomethyl)naphthoquinone Mannich bases: synthesis, crystal structure and cytotoxic activities.

机构信息

Instituto de Química, Campus do Valonguinho, Universidade Federal Fluminense, 24020-150, Niterói, RJ, Brazil.

出版信息

Dalton Trans. 2010 Nov 14;39(42):10203-16. doi: 10.1039/c0dt00572j. Epub 2010 Sep 24.

Abstract

The first examples of platinum(II) complexes of 3-(aminomethyl)naphthoquinone Mannich bases have been synthesised and their crystal structures are described. Neutral and charged complexes have been obtained, fully characterised and their cytotoxic activities have also been investigated. 3-[(R(1)-amino)(pyridin-2-yl)methyl]-2-hydroxy-1,4-naphthoquinones (R(1) = n-Bu, HL1; Bn, HL2; furfuryl, HL3; n-heptyl, HL4 and n-decyl, HL5) coordinate to platinum(II) through the two nitrogen atoms. The neutral complexes cis-[Pt(HL)Cl(2)] 1a-5a are analogous to cisplatin with the bidentate ligand HL and two chlorine atoms occupying cis positions. In the charged complexes cis-[Pt(L(-))(NH(3))(2)]NO(3)1b-5b the deprotonated form of the ligand L(-) also coordinates via the nitrogen atoms, and the other two positions around the platinum(II) ion are completed with NH(3) ligands. The cytotoxic activities of all compounds have been tested for six different cancer cell lines: MDA-MB-435 (melanoma), HL-60 (promyelocytic leukaemia), HCT-8 (colon), SF-295 (brain), OVCAR-8 (ovary) and PC-3 (prostate). Proligands HL4 and HL5 have exhibited high activity against HL-60 (IC(50) = 1.9 and 3.8 μmol L(-1), respectively), HCT-8 (IC(50) = 1.6 and 1.7 μmol L(-1), respectively) and SF-295 (IC(50) = 1.1 and 1.7 μmol L(-1), respectively). The chlorido complexes 1a-5a have shown high to moderate cytotoxic activities, complex 4a (R(1) = n-heptyl) being more active than proligand HL4 against melanoma (IC(50) = 6.4 and > 40 μmol L(-1), respectively) and more active than cisplatin against all tested cell lines. Among the amine charged complexes only 4b and 5b have exhibited significant cytotoxic activity against the tested cell lines, although they were only moderately active against the PC-3 cell line (IC(50) = 29.9 and 15.6 μmol L(-1), respectively). In general the compounds with the longest carbon chains (R(1) = n-heptyl and n-decyl) have exhibited the highest activities.

摘要

首例 3-(氨甲基)萘醌曼尼希碱的铂(II)配合物已被合成,并对其晶体结构进行了描述。得到了中性和带电配合物,对其进行了全面的表征,并研究了它们的细胞毒性活性。3-[(R(1)-氨基)(吡啶-2-基)甲基]-2-羟基-1,4-萘醌(R(1) = n-Bu,HL1;Bn,HL2;糠基,HL3;n-庚基,HL4 和 n-癸基,HL5)通过两个氮原子与铂(II)配位。中性配合物顺式-[Pt(HL)Cl(2)]1a-5a 类似于顺铂,其中双齿配体 HL 和两个氯原子占据顺式位置。在带电配合物顺式-[Pt(L(-))(NH(3))(2)]NO(3)1b-5b 中,配体 L(-)的去质子化形式也通过氮原子配位,而铂(II)离子周围的另外两个位置则由 NH(3)配体完成。所有化合物的细胞毒性活性都已在六种不同的癌细胞系中进行了测试:MDA-MB-435(黑色素瘤)、HL-60(早幼粒细胞白血病)、HCT-8(结肠)、SF-295(脑)、OVCAR-8(卵巢)和 PC-3(前列腺)。前体 HL4 和 HL5 对 HL-60(IC(50) = 1.9 和 3.8 μmol L(-1))、HCT-8(IC(50) = 1.6 和 1.7 μmol L(-1))和 SF-295(IC(50) = 1.1 和 1.7 μmol L(-1))表现出高活性。氯配合物 1a-5a 表现出高至中等的细胞毒性活性,配合物 4a(R(1) = n-庚基)对黑色素瘤的活性高于前体 HL4(IC(50) = 6.4 和 > 40 μmol L(-1)),对所有测试的细胞系的活性均高于顺铂。在胺基带电配合物中,只有 4b 和 5b 对测试的细胞系表现出显著的细胞毒性活性,尽管它们对 PC-3 细胞系的活性仅为中度(IC(50) = 29.9 和 15.6 μmol L(-1))。一般来说,碳链最长的化合物(R(1) = n-庚基和 n-癸基)表现出最高的活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验